NCT04820530View on ClinicalTrials.gov

Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 19, 2021

Primary Completion Date

November 2, 2022

Study Completion Date

April 18, 2023

Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
DRUG

Iptacopan (LNP023)

Taken orally b.i.d. Dosage supplied: 200mg Dosage form: Hard gelatin capsule Route of Administration: oral

Trial Locations (12)

45147

Novartis Investigative Site, Essen

52074

Novartis Investigative Site, Aachen

75475

Novartis Investigative Site, Paris

83100

Novartis Investigative Site, Avellino

88586

Novartis Investigative Site, Kota Kinabalu

93586

Novartis Investigative Site, Kuching

100730

Novartis Investigative Site, Beijing

119228

Novartis Investigative Site, Singapore

300020

Novartis Investigative Site, Tianjin

300052

Novartis Investigative Site, Tianjin

06351

Novartis Investigative Site, Seoul

SE5 9RS

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY